This resource was created by SMI Adviser content partners and approved by the SMI Adviser clinical expert team for inclusion in the knowledge base.
NAMI and SMI Adviser would like to share important updates with our members, their families, and others who take clozapine (Clozaril, FazaClo, or Versacloz) to manage a mental health condition. There have been updates to the Clozapine Risk Evaluation and Mitigation Strategies (REMS) Program, a system used by prescribers and pharmacies to ensure the safe, effective use of this medication.
Any changes to how clozapine is prescribed, what blood work is required, or how it’s dispensed from pharmacies, could affect anyone who is taking clozapine as a part of their treatment plan. This information is being shared to prevent potential interruptions in treatment, and help you communicate with clinicians and pharmacists as they transition to this new system.